Physician Info

This was the “top news” category. Now the physician info category. It gets filtered out by the mechanism that sends emails to SGLs and others when there is a new post. It is also filtered out by the blogs on all pages except the Archive and Physician Info page.

Essential Information: A Physician’s Guide

2023-11-17T16:45:46-05:00

This booklet provides a compilation of current knowledge on the diagnosis, treatment, and established protocols for WM.  Complete with references to published papers, throughout, it has been modified with a small number of Canadian-specific footnotes.  Authored by two WM specialist MDs from the Bing Center for WM at the Dana-Farber Cancer Institute, it is presented in partnership with the International Waldenstrom's Macroglobulinemia Foundation (IWMF).

Essential Information: A Physician’s Guide2023-11-17T16:45:46-05:00

Zanubrutinib vs Ibrutinib in Symptomatic WM: Final Analysis From the Randomized Phase III ASPEN Study

2023-08-04T08:31:19-04:00

Quoting from the paper, published in ASCO's Journal of Clinical Oncology: "Extended follow-up results confirm improved long-term safety and tolerability of zanubrutinib compared with ibrutinib and support deeper, earlier, and more durable responses in patients with WM regardless of previous treatment or CXCR4 and MYD88 mutational statuses."

Zanubrutinib vs Ibrutinib in Symptomatic WM: Final Analysis From the Randomized Phase III ASPEN Study2023-08-04T08:31:19-04:00

IWWM-11: Highlights of the Workshop, and What was Learned

2023-06-18T13:08:10-04:00

A concise summary of the entire 11th International Workshop on WM, entitled What we learned, and how it will impact scientific discovery and patient care, is available here, as published in the journal Seminars in Hematology.

IWWM-11: Highlights of the Workshop, and What was Learned2023-06-18T13:08:10-04:00

Diagnostic and Response Criteria: IWWM-11 Consensus Panel 4

2023-04-20T08:15:56-04:00

Consensus Panel 4 (CP4) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with reviewing the current criteria for diagnosis and response assessment.  Their report is available here.

Diagnostic and Response Criteria: IWWM-11 Consensus Panel 42023-04-20T08:15:56-04:00

Management of WM-Related Amyloidosis: IWWM-11 Consensus Panel 6

2023-04-18T21:09:54-04:00

Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenström macroglobulinemia (WM).  Their report is available here.

Management of WM-Related Amyloidosis: IWWM-11 Consensus Panel 62023-04-18T21:09:54-04:00

Clinical Trial Priorities for WM: IWWM-11 Consensus Panel 7

2023-04-15T17:13:28-04:00

Consensus Panel 7 (CP7) of the 11th International Workshop on WM was convened to examine the current generation of completed and ongoing clinical trials involving novel agents, consider updated data on WM genomics, and make recommendations on the design and prioritization of future clinical trials.  Their report is available here.

Clinical Trial Priorities for WM: IWWM-11 Consensus Panel 72023-04-15T17:13:28-04:00

COVID-19 Prophylaxis and Management: IWWM-11 Consensus Panel 5

2023-04-15T17:08:34-04:00

Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the current data on the coronavirus disease-2019 (COVID-19) prophylaxis and management in patients with Waldenstrom's Macroglobulinemia (WM).  Their report is available here.

COVID-19 Prophylaxis and Management: IWWM-11 Consensus Panel 52023-04-15T17:08:34-04:00

Recommendations for Molecular Diagnosis in WM: IWWM-11 Consensus Panel 3

2023-04-15T17:06:15-04:00

Consensus Panel 3 (CP3) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the current molecular necessities and best way to access the minimum data required for a correct diagnosis and monitoring.  Their report is available here.

Recommendations for Molecular Diagnosis in WM: IWWM-11 Consensus Panel 32023-04-15T17:06:15-04:00

Management of Relapsed or Refractory WM Patients: IWWM-11 Consensus Panel 2

2023-04-15T17:02:41-04:00

The Consensus Panel 2 (CP2) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) has reviewed and incorporated current data to update the recommendations for treatment approaches in patients with relapsed or refractory WM (RRWM).  Their report is available here.

Management of Relapsed or Refractory WM Patients: IWWM-11 Consensus Panel 22023-04-15T17:02:41-04:00

Management of Symptomatic, Treatment-Naïve Patients: IWWM-11 Consensus Panel 1

2023-04-15T16:59:59-04:00

Consensus Panel 1 (CP1) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with updating guidelines for the management of symptomatic, treatment-naïve patients with WM.  Their report is available here.

Management of Symptomatic, Treatment-Naïve Patients: IWWM-11 Consensus Panel 12023-04-15T16:59:59-04:00
Go to Top